Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis

Next Previous
Trial Profile

A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXCEED; EXCEED 1
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 25 Apr 2023 Results post hoc analysis of the EXCEED study, evaluating Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab, published in the Rheumatology
  • 09 Nov 2021 Results of post hoc, descriptive analysis of patients in the EXCEED assessing enthesitis presented at the ACR Convergence 2021
  • 05 Jun 2021 Results of a post hoc analysis to explore detailed enthesitis treatment response, including temporal and additional enthesitis presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top